Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products
Halozyme Therapeutics' record-breaking 2024 revenue exceeded $1B, with strong 2025 growth projections led by DARZALEX & VYVGART.
FiercePharma14h
Argenx puts marketing muscle behind CIDP launch with Vyvgart Hytrulo TV campaign
Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory ...